GSK Expands its License Agreement with Zymework to Develop and Commercialize Bi-Specific Antibodies

 GSK Expands its License Agreement with Zymework to Develop and Commercialize Bi-Specific Antibodies

GSK Expands its License Agreement with Zymework to Develop and Commercialize Bi-Specific Antibodies

Shots:

  • Zymework to receive preclinical, development & commercial milestone payments and royalties on WW sales. GSK to get an option to develop and commercialize bi-specific candidates for multiple indications including infectious diseases utilizing Zymeworks’ heavy-light chain pairing technology of Azymetric platform
  • In 2016, the companies collaborated to develop & commercialize up to six bispecific antibodies utilizing Zymeworks’s Azymetric platform
  • Zymeworks’s Azymetric platform allows the transformation of monospecific Ab to bispecific Ab, enabling it to bind with two different targets, thus reducing toxicities and drug resistance        

Click here to read full press release/ article | Ref: Business Wire | Image: The Hindu Business Line

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post